Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Neural blocking therapy

a neuronal activity and blocking technology, applied in the direction of therapy, internal electrodes, head electrodes, etc., can solve the problems of no therapy achieved by blocking, dopamine cannot be administered directly to patients, and the effect of “wearing off”

Inactive Publication Date: 2007-03-29
FLATHEAD PARTNERS LLC +1
View PDF99 Cites 265 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The patent describes a method and device for treating various conditions by using an electrode to create a field that blocks neural activity in a specific area of the brain, spinal cord, or tissue. The treatment can be used to treat disorders associated with neural activity in these areas. The technical effect of this invention is to provide a non-invasive and effective way to treat conditions associated with neural activity."

Problems solved by technology

No therapy is achieved by the blocking.
Unfortunately, dopamine cannot be administered directly to patients because it does not cross the blood-brain barrier.
However, patients taking Sinemet for a longer period are prone to the “wearing-off” effect, a tendency for the effectiveness of the drug to be lost with time.
Hence, the dose of Sinemet will often have to be increased with time.
Moreover, as the dose of the medication is increased, some patients begin to experience side effects due an increase in brain dopamine levels.
The occurrence of side effects limits the further increase in Sinemet's dosage and at this point, treatment options become limited.
Furthermore, although levodopa / carbidopa treatment decreases bradykinesia and rigidity, it may not relieve tremor and balance.
Moreover, levodopa has a very short plasma half-life.
However, selegiline has its drawbacks.
Patients have been known to experience side effects such as nausea, orthostatic hypotension and insomnia.
However, these two drugs are less effective than L-DOPA in decreasing bradykinesia and rigidity and induce side effects such as paranoia, hallucinations, confusion, nausea and vomiting.
However, its effectiveness is known to wear off in a third to a half of the patients taking it.
Furthermore, it induces side effects such as edema, blurred vision, depression, confusion and mottled skin.
While effective, these drugs can also have side effects such as blurred vision, urinary retention, dry mouth, memory loss, and constipation.
Hence, they are of limited use to the older population because they can cause serious neuropsychiatric side effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Neural blocking therapy
  • Neural blocking therapy
  • Neural blocking therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0050] With reference now to the various drawing figures in which identical elements are identically numbered, preferred embodiments of the present invention will now be described.

[0051] A. Central Nervous System (CNS) Treatment

[0052] Certain disorders (e.g., epilepsy and Parkinson's disease and other motor disorders of CNS origin) are believed to be associated with hormonal imbalance.

[0053] Movement disorders associated with cerebral activity are not fully understood. However, certain disorders such as epilepsy and Parkinson's disease are believed to be associated with an imbalance of hormonal production deep within the brain.

[0054] For example, certain regions deep within the brain produce the hormones glutamate and dopamine. Glutamate enhances conductivity of the nerve cells of the brain while dopamine reduces or inhibits such conductivity.

[0055] With reference to FIG. 3, dopamine is produced within a region of the brain known as the substantia nigra SN. Glutamate is produce...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A method and apparatus are disclosed for treating a variety of conditions include treating a disorder associated with neural activity near a region of a brain. In such condition, the method includes placing an electrode to create a field near said region, creating said field with parameters selected to at least partially block neural activity within said field. For treating a tissue sensation, the method includes identifying a target area of tissue to be treated and placing an electrode to create a field near the target area, and creating the field with parameters selected to at least partially block neural activity within the target area. For treating a condition associated with neural activity of a spinal cord, the method includes placing an electrode to create a field near a nerve associated with the spinal cord, and creating the field with parameters selected to at least partially block neural activity within the nerve.

Description

I. BACKGROUND OF THE INVENTION [0001] 1. Field of the Invention [0002] This application pertains to method and apparatus for treating conditions associated with neuronal activity. [0003] 2. Description of the Prior Art [0004] a. Neural Stimulation Treatments [0005] The prior art contains numerous examples of treatments involving stimulation signals to nerves, muscles or organs for treating a wide variety of medical disorders. [0006] U.S. Pat. Nos. 4,702,254 and 5,229,569 (both assigned to Cyberonics, Inc.) describe various central nervous system (CNS) treatments using electrical stimulation applied to the vagus nerve. For example, the '254 patent describes treatment of epilepsy. The '569 patent describes treatment of neuropsychiatric disorders. U.S. patent application Publ. No. 2003 / 0144709 (also assigned to Cyberonics, Inc.) describes treatment of pain through nerve stimulation. [0007] U.S. patent application publication No. 2004 / 0243205 A1 to Keravel et al. published Dec. 2, 2004 ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61N1/00
CPCA61N1/0531A61N1/0534A61N1/36067A61N1/36064A61N1/0551A61N1/36071
Inventor KNUDSON, MARK B.DONDERS, ADRIANUS P.CONRAD, TIMOTHY R.
Owner FLATHEAD PARTNERS LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products